Her areas of expertise include the cutting-edge early market access schemes that are being trialed around the world for taking drugs and medical devices to market faster. She is also interested in initiatives for harmonizing regulations at the global level as well as issues affecting clinical trials, manufacturing and post-market safety monitoring. She explores the challenges and opportunities that these issues introduce for both industry and the regulators and is on a constant look out for what might be coming next.
A scientist by training, Neena started her journalistic career at Informa in 1997. She has been the deputy editor of Scrip Regulatory Affairs since 2007. Prior to that, she worked as the science editor for Clinica Medtech Intelligence. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Neena Brizmohun
Seven new drugs have this week moved closer to gaining EU approval following positive recommendations from the European Medicines Agency, but Emmaus’ glutamine product has fared less well and the company is considering another route for getting the drug to sickle cell disease patients in Europe
Vertex’s triple combination regimen for cystic fibrosis and two Ebola vaccines from Janssen are among the latest potential new products being considered for accelerated assessment by the European Medicines Agency.
Scotland’s health technology assessment body has reversed its earlier decision to reject Kymriah for DLBCL.
New medicines under evaluation at the European Medicines Agency.
The Danish Medicines Agency is testing a new regulatory advice service that medical device SMEs and start-ups anywhere in the world can apply to use.
The Therapeutic Goods Administration is seeking feedback on proposals affecting manufacturers of packages containing therapeutic goods, at least one of which is a medical device or IVD.